ACHN


Achillion Pharmaceuticals, Inc. (ACHN) Shares Skyrocket Following 2Q:17 Results and Clinical Update

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported financial results for the three and six months ended June 30, 2017.

Here’s Why Maxim Slashed Price Target on Achillion Pharmaceuticals, Inc. (ACHN) Today

Maxim analyst Jason Kolbert slashes his price target on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $5.

Stock Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Announces $15 Million Clinical Milestone for JNJ-4178 in Phase 2B Development for Chronic HCV

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC.

Company Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Announces Initiation of Patient Dosing by Janssen in Phase 2b Study of JNJ-4178 in Chronic HCV

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the start of patient dosing in a global Phase 2b open-label OMEGA-1 study of JNJ-4178, a 3DAA combination …

Achillion Pharmaceuticals (ACHN) Shares Might’ve Just Hit A Bottom; Chardan Upgrades

In a research report released Friday, Chardan analyst Madhu Kumar upgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to a Neutral rating, without providing a price …

Analysts Speculate on Two Falling Biotech Stocks: Achillion Pharmaceuticals, Inc. (ACHN) and bluebird bio Inc (BLUE)

News from Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and bluebird bio Inc (NASDAQ:BLUE) have sent biotech investors running for the hills and have left shares …

Achillion Pharmaceuticals, Inc. (ACHN) Provides 3Q:16 Update; Shares Fall 19%

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported financial results for the three months ended September 30, 2016.

Company Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Announces Updated Interim Results From Janssen’s Phase 2 Trial in Genotype 1 Treatment-Naïve HCV

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios …

Company Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the presentation of two posters which detailed novel preclinical research into complement biology and the inhibition of factor D …